文献速递角膜与眼表疾病

用于治疗细菌性角膜炎的设计宿主防御肽

Designed Host Defense Peptides for the Treatment of Bacterial Keratitis.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2017-01-01

本研究测定新型设计宿主防御肽(dHDPs)对革兰阳性与阴性菌的最低抑菌浓度(MICs 2至>64 μg/mL)和最低生物膜根除浓度(MBEC 6至750 μg/mL),并在体外快速杀菌;最活跃的RP444在鼠铜绿假单胞菌角膜炎模型中显著剂量依赖性降低眼部临床评分、细菌负荷和炎症细胞浸润,且反复亚抑菌浓度暴露未诱导耐药。

要点

  • dHDPs对革兰阳性与阴性菌均有杀菌活性,MICs为2至>64 μg/mL,MBEC为6至750 μg/mL。
  • RP444在体外时间-杀菌试验中低至2 μg/mL即可快速降低细菌计数。
  • RP444反复亚抑菌浓度暴露铜绿假单胞菌未诱导耐药,并在鼠角膜炎模型中显著剂量依赖性降低临床评分、细菌负荷和炎症细胞浸润。

核心结论

  • 新型dHDPs具有强效抗菌活性、耐药诱导潜力有限,并减轻鼠铜绿假单胞菌角膜炎严重程度。
  • 研究提示新型dHDP可能具有治疗威胁视力的细菌性角膜炎患者的潜力。

研究设计与样本

  • 体外测定dHDPs对革兰阳性与阴性菌的最低抑菌浓度(MICs)、最低生物膜根除浓度(MBEC)及时间-杀菌试验。
  • 评估最活跃dHDP RP444诱导耐药倾向,并在鼠铜绿假单胞菌角膜炎模型中评价疗效。

主要发现

  • dHDPs为杀菌性,MICs范围为2至>64 μg/mL,MBEC范围为6至750 μg/mL。
  • 时间-杀菌试验中,dHDPs接触低至2 μg/mL即可快速降低细菌计数。
  • RP444反复暴露于亚抑菌浓度铜绿假单胞菌后未诱导耐药。
  • RP444在鼠细菌性角膜炎模型中显示显著疗效:眼部临床评分显著剂量依赖性降低、细菌负荷显著减少、炎症细胞浸润大幅减少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To limit corneal damage and potential loss of vision, bacterial keratitis must be treated aggressively. Innovation in antimicrobials is required due to the need for empirical treatment and the rapid emergence of bacterial resistance. Designed host defense peptides (dHDPs) are synthetic analogues of naturally occurring HDPs, which provide defense against invading pathogens. This study investigates the use of novel dHDPs for the treatment of bacterial keratitis. METHODS: The minimum inhibitory concentrations (MICs) were determined for dHDPs on both Gram-positive and -negative bacteria. The minimum biofilm eradication concentrations (MBEC) and in vitro time-kill assays were determined. The most active dHDP, RP444, was evaluated for propensity to induce drug resistance and therapeutic benefit in a murine Pseudomonas aeruginosa keratitis model. RESULTS: Designed HDPs were bactericidal with MICs ranging from 2 to >64 μg/mL and MBEC ranging from 6 to 750 μg/mL. In time-kill assays, dHDPs were able to rapidly reduce bacterial counts upon contact with as little as 2 μg/mL. RP444 did not induce resistance after repeated exposure of P. aeruginosa to subinhibitory concentrations. RP444 demonstrated significant efficacy in a murine model of bacterial keratitis as evidenced by a significant dose-dependent decrease in ocular clinical scores, a significantly reduced bacterial load, and substantially decreased inflammatory cell infiltrates. CONCLUSIONS: Innovative dHDPs demonstrated potent antimicrobial activity, possess a limited potential for development of resistance, and reduced the severity of murine P. aeruginosa keratitis. These studies demonstrate that a novel dHDP may have potential to treat patients with sight-threatening bacterial keratitis.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Clemens LE, Jaynes J, Lim E, et al. Designed Host Defense Peptides for the Treatment of Bacterial Keratitis. Invest Ophthalmol Vis Sci. 2017. PMID: 29242901. doi:10.1167/iovs.17-22243

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。